The EMA And EU Expansion - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The EMA And EU Expansion
In addition to coordinating centralised authorisation procedures for medicines, the EMA is responsible for a number of other tasks, and must rely heavily on the involvement of the EU member states and the countries of the European Economic Area. The greatest challenge faced by the agency, however, is the continuing expansion of the EU.


Pharmaceutical Technology Europe
Volume 23, Issue 6

References

1. Europa, "The 2004 enlargement: the challenge of a 25-member EU", Europa website 2007. http://europa.eu/ (accessed 12 May 2011)

2. I. Eckhart, "The European Medicines Agency (EMEA) — from Research to Therapies", Bridges 11 2006. http://www.ostina.org/ (accessed 12 May 2011)

3. EMA, "European Union enlargement. EMA", EMA website 2011. http://www.ema.europa.eu/ (accessed 12 May 2011)

4. Anon., "EMEA in the European system", Bull. Soc. Sci. Med. 1/2004, 87–92 (2004).

5. IDABC, "EUDRANET: European Telecommunication Network in Pharmaceuticals (EMEA)", Europa website 2004. http://ec.europa.eu/ (accessed 12 May 2011)

6. EMA, "EU Regulatory Network - Challenges and Opportunities for Croatia", EMA website 2008. http://www.emea.europa.eu/htms/euenlargement (accessed 12 May 2011)

7. EMA, "Successful Rijeka conference strengthens EU-Croatian cooperation on medicines regulation", EMA website 2008. http://www.ema.europa.eu/ (accessed 12 May 2011)

8. H. Prange, Queen's Papers on Europeanisation No 8/2002 (2002). http://www.qub.ac.uk92/ (accessed 12 May 2011).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology Europe,
Click here